|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/04 | (2006.01) |
| C07K 14/35 | (2006.01) | ||
| A61P 31/06 | (2006.01) |
| (11) | Number of the document | 2163255 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09172905.3 |
| Date of filing the European patent application | 2006-06-20 | |
| (97) | Date of publication of the European application | 2010-03-17 |
| (45) | Date of publication and mention of the grant of the patent | 2017-08-09 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 200500924 | 2005-06-23 | DK | |
| 200501393 | 2005-10-05 | DK |
| (72) |
Vingsbo-Lundberg, Carina, SE
Aagaard, Claus, DK
Andersen, Peter, DK
|
| (73) |
Statens Serum Institut,
Artillerivej 5, 2300 Copenhagen S,
DK
|
| (54) | Tuberculosis vaccines comprising antigens expressed during the latent infection phase |
| Tuberculosis vaccines comprising antigens expressed during the latent infection phase |